Thyroid dysfunction in patients with childhood-onset medulloblastoma or primitive neuroectodermal tumor
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We investigated the clinical characteristics of patients who developed thyroid dysfunction and evaluated the risk factors for hypothyroidism following radiotherapy and chemotherapy in pediatric patients with medulloblastoma or primitive neuroectodermal tumor (PNET). Methods: The medical records of 66 patients (42 males) treated for medulloblastoma (n=56) or PNET (n=10) in childhood between January 2000 and December 2014 at Seoul National University Children’s Hospital were retrospectively reviewed. A total of 21 patients (18 high-risk medulloblastoma and 3 PNET) underwent high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) Results: During the median 7.6 years of follow-up, 49 patients (74%) developed transient (n=12) or permanent (n=37) hypothyroidism at a median 3.8 years of follow-up (2.9–4.6 years). Younger age (<5 years) at radiation exposure (P=0.014 vs. ≥9 years) and HDCT (P=0.042) were significantly predictive for hypothyroidism based on log-rank test. However, sex, type of tumor, and dose of craniospinal irradiation (less vs. more than 23.4 Gy) were not significant predictors. Cox proportional hazard model showed that both younger age (<5 years) at radiation exposure (hazard ratio [HR], 3.1; vs. ≥9 years; P=0.004) and HDCT (HR, 2.4; P=0.010) were significant predictors of hypothyroidism. Conclusion: Three-quarters of patients with pediatric medulloblastoma or PNET showed thyroid dysfunction, and over half had permanent thyroid dysfunction. Thus, frequent monitoring of thyroid function is mandatory in all patients treated for medulloblastoma or PNET, especially, in very young patients and/or high-risk patients recommended for HDCT/ASCR.
Abstract
Purpose: We investigated the clinical characteristics of patients who developed thyroid dysfunction and evaluated the risk factors for hypothyroidism following radiotherapy and chemotherapy in pediatric patients with medulloblastoma or primitive neuroectodermal tumor (PNET). Methods: The medical records of 66 patients (42 males) treated for medulloblastoma (n=56) or PNET (n=10) in childhood between January 2000 and December 2014 at Seoul National University Children’s Hospital were retrospectively reviewed. A total of 21 patients (18 high-risk medulloblastoma and 3 PNET) underwent high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) Results: During the median 7.6 years of follow-up, 49 patients (74%) developed transient (n=12) or permanent (n=37) hypothyroidism at a median 3.8 years of follow-up (2.9–4.6 years). Younger age (<5 years) at radiation exposure (P=0.014 vs. ≥9 years) and HDCT (P=0.042) were significantly predictive for hypothyroidism based on log-rank test. However, sex, type of tumor, and dose of craniospinal irradiation (less vs. more than 23.4 Gy) were not significant predictors. Cox proportional hazard model showed that both younger age (<5 years) at radiation exposure (hazard ratio [HR], 3.1; vs. ≥9 years; P=0.004) and HDCT (HR, 2.4; P=0.010) were significant predictors of hypothyroidism. Conclusion: Three-quarters of patients with pediatric medulloblastoma or PNET showed thyroid dysfunction, and over half had permanent thyroid dysfunction. Thus, frequent monitoring of thyroid function is mandatory in all patients treated for medulloblastoma or PNET, especially, in very young patients and/or high-risk patients recommended for HDCT/ASCR.
참고문헌 (25)
- Ostrom QT, "CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013", Neuro Oncol, 18(suppl_5), pp.v1~v75 (2016)[DOI]
- Massimino M, "Childhood medulloblastoma", Crit Rev Oncol Hematol, 105, pp.35~51 (2016)[DOI]
- Packer RJ, "Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma", J Clin Oncol, 24, pp.4202~4208 (2006)[DOI]
- Jereczek-Fossa BA, "Radiotherapy-induced thyroid disorders", Cancer Treat Rev, 30, pp.369~384 (2004)[DOI]
- Constine LS, "Thyroid dysfunction after radiotherapy in children with Hodgkin's disease", Cancer, 53, pp.878~883 (1984)[DOI]
- 이현주, "Subclinical Hypothyroidism in Childhood Cancer Survivors", Yonsei Medical Journal, 57(4), pp.915~922 (2016), 연세대학교의과대학[DOI]
- Paulino AC, "Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy craniospinal radiotherapy", Int J Radiat Oncol Biol Phys, 53, pp.543~547 (2002)[DOI]
- Hamnvik OP, "Thyroid dysfunction from antineoplastic agents", J Natl Cancer Inst, 103, pp.1572~1587 (2011)[DOI]
- Yeung SC, "The endocrine effects of nonhormonal antineoplastic therapy", Endocr Rev, 19, pp.144~172 (1998)[DOI]
- Sarkar C, "Medulloblastomas: new directions in risk stratification", Neurol India, 54, pp.16~23 (2006)[DOI]
- Kim H, "Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed edulloblastoma", PNET in pediatric patients, 2013, pp.29, 1851~1858
- 박준은, "Efficacy of High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Relapsed Medulloblastoma: A Report on The Korean Society for Pediatric Neuro-Oncology (KSPNO)-S-053 Study", Journal of Korean Medical Science, 25(8), pp.1160~1166 (2010), 대한의학회
- Shih CS, "High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors", Cancer, 112, pp.1345~1353 (2008)[DOI]
- Yoon JH, "Treatment of pediatric average-risk medulloblastoma using craniospinal irradiation less than 2500 cGy and chemotherapy: single center experience in Korea", World J Pediatr, 13, pp.367~373 (2017)[DOI]
- Clement SC, "Prevalence and risk factors of early endocrine disorders in childhood brain tumor survivors: a nationwide, multicenter study", J Clin Oncol, 34, pp.4362~4370 (2016)[DOI]
- Rose SR, "Late endocrine effects of childhood cancer", Nat Rev Endocrinol, 12, pp.319~336 (2016)[DOI]
- Saha A, "Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols", Pediatr Blood Cancer, 61, pp.1644~1652 (2014)[DOI]
- Chin D, "Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma", primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy, 1997, pp.80, 798~804
- 윤인석, "소아 수모세포종 환자에서 치료 후의 내분비적 장애와 성장변화", Clinical and Experimental Pediatrics, 49(3), pp.292~297 (2006), 대한소아청소년과학회
- Sobol G, "The evaluation of function and the ultrasonographic picture of thyroid in children treated for medulloblastoma", Childs Nerv Syst, 28, pp.399~404 (2012)[DOI]
- Ogilvy-Stuart AL, "Thyroid function after treatment of brain tumors in children", J Pediatr, 119, pp.733~737 (1991)[DOI]
- Massart C, "Effects of cisplatin on human thyrocytes in monolayer or follicle culture", J Mol Endocrinol, 8, pp.243~248 (1992)[DOI]
- Stuart NS, "Longterm toxicity of chemotherapy for testicular cancer--the cost of cure", Br J Cancer, 61, pp.479~484 (1990)[DOI]
- Torino F, "Thyroid dysfunction as an unintended side effect of anticancer drugs", Thyroid, 23, pp.1345~1366 (2013)[DOI]
- Massimino M, "Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma", primitive neuroectodermal tumor, 2007, pp.69, 404~410